Objetivo The objective of this project is to develop a business plan for the continued clinical development and commercialisation of ALZ-101 – a novel therapeutic Alzheimer´s disease (AD) vaccine candidate designed to prevent neurodegeneration in the brain. AD is a therapeutic area in dire need of effective treatments. The disease, which primarily afflicts the elderly (65+), irreversbly destroys brain cells and affects the patient’s cognitive ability. The exact mechanisms leading to AD are unknown. However, it has been found that the disease is linked to the aggregation and deposition of Aβ1-42 – one of the isoforms of fibrous Aβ peptide - into senile plaques in the brain.In recent years, significant efforts have been made to attempt targeting the clearance of Aβ1-42 through the administration of Aβ antigens (active immunotherapy) or anti-Aβ anti-bodies (passive immunotherapy). However, the development has been fraught with difficulties. Aβ1-42 oligomers are inherently unstable and heterogeneous. This precludes the development of efficient therapies. Alzinova owns the AβCC peptide™ technology which allows for the development of a vaccine that specifically targets the endogenous substance that causes disease – a feat made possible by the unprecedented capability to stabilise the antigen.The product will be ready to enter the clinical trial in humans by the end of 2017. In the Phase 1 project, we will develop a business plan that will guide the future clinical studies and commercialisation (to be included in the Phase 2 project). The strategy is to take the product to the Phase I/IIa level and thereafter acquire strategic partner for continued clinical studies and market launch.Fighting AD is an EU-wide challenge as it affects 7.3 million people within the EU-27 countries. The effects of AD are devastating not only for the patients, but also for their families. ALZ-101 delivers in this context a strong EU-added value by its potential to stop the progression of AD. Ámbito científico medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health sciencesbasic medicineneurologydementiaalzheimermedical and health sciencesclinical medicinepsychiatrymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccinesmedical and health sciencesbasic medicineimmunologyimmunotherapy Programa(s) H2020-EU.2.1.4. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology Main Programme H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Tema(s) SMEInst-03-2016-2017 - Dedicated support to biotechnology SMEs closing the gap from lab to market Convocatoria de propuestas H2020-SMEInst-2016-2017 Consulte otros proyectos de esta convocatoria Convocatoria de subcontratación H2020-SMEINST-1-2016-2017 Régimen de financiación SME-1 - SME instrument phase 1 Coordinador ALZINOVA AB Aportación neta de la UEn € 50 000,00 Dirección ERIK DAHLBERGSGATAN 11 A 411 26 GOTEBORG Suecia Ver en el mapa Pyme Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención. Sí Región Södra Sverige Västsverige Västra Götalands län Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Enlaces Contactar con la organización Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 71 429,00
